Champions Oncology, Inc. (CSBR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 43/100 (MEDIUM), 14.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.37% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI
- CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
- Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ...
- Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript
- Champions Oncology, Inc. Q1 2027 Earnings Call Summary
- Champions Oncology Q1 Earnings Call Highlights
- Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
- Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Champions Oncology, Inc..
Full CSBR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.